Datapoint: HyQvia Scores Second FDA Nod

The FDA on Jan. 16 approved Takeda’s HyQvia as a maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP), a progressive autoimmune disease that causes weakness over time. The subcutaneous immune globulin infusion can be administered every two, three or four weeks, and at-home use is an option for some patients. This is HyQvia’s second indication — it was first approved in 2014 for the treatment of primary immunodeficiency (PI). For this indication, it currently holds covered or better status for 95% of all insured lives under the medical benefit. 21% of lives have covered access without utilization management restrictions.

SOURCE: MMIT Analytics, as of 1/17/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today